• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Irinotecan Injection
    / Pfizer

    Active Ingredient
    Irinotecan HCl 20 mg/ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Solution for Infusion

    2 ml x 20 mg/ml

    partial basket chart 87955 9290

    Solution for Infusion

    5 ml x 20 mg/ml

    partial basket chart 87956 9291

    Solution for Infusion

    25 ml x 20 mg/ml

    partial basket chart 55600 9781


    Treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease; as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Treatment of patients with small cell lung cancer. Treatment of patients with gastric cancer.


    Chronic inflammatory bowel disease and/or bowel obstruction. Hypersensitivity to irinotecan or any of the excipients. Pregnancy and lactation. Bilirubin >3 times the upper limit of the normal range, severe bone marrow failure, WHO performance status >2, concomitant use with St. John? Wort.

    Special Precautions

    Should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.
    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.


    Drug interactions

    Neuromuscular blocking agents. CYP3A-inducing anticonvulsant drugs (e.g., rifampicin, carbamazepine, phenobarbital or phenytoin). Consideration should be given to starting or substituting non-enzyme-inducing anticonvulsants at least one week prior to initiation of irinotecan therapy (e.g., ketoconazole) in patients requiring anticonvulsant treatment.

    Hospira Inc.